2023-2027 North America Hemostasis Analyzers and Reagents USA, Canada, Mexico Chromogenic, Immunodiagnostic, Molecular Coagulation Test Volume and Sales Segment Forecasts 2023 Competitive Shares and Growth Strategies, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers
This new 3-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.The report is available by section, and can be customized to specific information needs and budget.
The report explores business and technological trends; provides test volume and sales forecasts for 40 hemostasis procedures; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
Rationale
The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromogenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, IT and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.
New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
Coagulation Tests Analyzed in the Report
Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.
Country Analyses
Canada, Mexico, USA
Competitive Assessments
Extensive strategic profiles of major suppliers and emerging market entrants.
Current and Emerging Products
Review of established and emerging procedures.
Comparison of automated and semi-automated analyzers marketed by Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.
Technology Review
Analysis of current and emerging technologies and their potential market applications.
Companies developing or marketing new technologies and products by test.
Strategic Recommendations
Product development and business expansion opportunities with significant market appeal.
Ideal product models with tentative prices and operating characteristics.
Alternative market penetration strategies for instrument and reagent suppliers.
The report explores business and technological trends; provides test volume and sales forecasts for 40 hemostasis procedures; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
Rationale
The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromogenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, IT and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.
New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
Coagulation Tests Analyzed in the Report
Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.
Country Analyses
Canada, Mexico, USA
Competitive Assessments
Extensive strategic profiles of major suppliers and emerging market entrants.
Current and Emerging Products
Review of established and emerging procedures.
Comparison of automated and semi-automated analyzers marketed by Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.
Technology Review
Analysis of current and emerging technologies and their potential market applications.
Companies developing or marketing new technologies and products by test.
Strategic Recommendations
Product development and business expansion opportunities with significant market appeal.
Ideal product models with tentative prices and operating characteristics.
Alternative market penetration strategies for instrument and reagent suppliers.
- Potential market entry barriers and risks.
I. INTRODUCTION
II. MARKET OVERVIEW
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
VII. MARKET AND TECHNOLOGY OVERVIEW
A. Major Routine and Special Coagulation Tests
1. Introduction
2. Activated Partial Thromboplastin Time (APTT)
3. Alpha-2 Antiplasmin
4. Antithrombin III
5. Bleeding Time
6. D-Dimer
7. Ethanol Flocculation Test
8. Euglobulin Lysis
9. Factor Assays
a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII
10. Fibrin Degradation Products
11. Fibrinogen
12. Heparin
13. Hirudin
14. Hypercoagulability and Thrombosis
15. Lipoprotein a
16. Plasmin
17. Plasminogen
Table of Contents (continued)
18. Plasminogen Activator Inhibitor (PAI)
19. Platelet Function Tests
20. Platelet Aggregation
21. Proteins C and S
22. Prothrombin Fragment 1.2
23. Prothrombin Time (PT)
24. Reptilase Time
25. Thrombin Time
26. Tissue-Type Plasminogen Activator (t-PA)
27. Von Willebrand's Factor
B. Coagulation Instrumentation Review: Centralized
And POC Testing Analyzers
C. Major Coagulation Testing Technologies
And Their Potential Applications
VIII. COUNTRY MARKET ANALYSES: MARKET SIZE, REAGENT AND INSTRUMENT SALES FORECASTS, VOLUME
Projections for 40 Procedures, Supplier Sales and Market Shares
- Canada
- Mexico
- USA
Table of Contents (continued)
IX. Competitive Assessments
The report provides strategic assessments of over 20 leading coagulation market
players and start-up companies with innovative technologies and
products, including:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Diagnostica Stago
Grifols
Helena Laboratories
IL/Werfen
Roche
Sekisui Diagnostics
Siemens Healthineers
Sysmex
Thermo Fisher, and others
II. MARKET OVERVIEW
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
VII. MARKET AND TECHNOLOGY OVERVIEW
A. Major Routine and Special Coagulation Tests
1. Introduction
2. Activated Partial Thromboplastin Time (APTT)
3. Alpha-2 Antiplasmin
4. Antithrombin III
5. Bleeding Time
6. D-Dimer
7. Ethanol Flocculation Test
8. Euglobulin Lysis
9. Factor Assays
a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII
10. Fibrin Degradation Products
11. Fibrinogen
12. Heparin
13. Hirudin
14. Hypercoagulability and Thrombosis
15. Lipoprotein a
16. Plasmin
17. Plasminogen
Table of Contents (continued)
18. Plasminogen Activator Inhibitor (PAI)
19. Platelet Function Tests
20. Platelet Aggregation
21. Proteins C and S
22. Prothrombin Fragment 1.2
23. Prothrombin Time (PT)
24. Reptilase Time
25. Thrombin Time
26. Tissue-Type Plasminogen Activator (t-PA)
27. Von Willebrand's Factor
B. Coagulation Instrumentation Review: Centralized
And POC Testing Analyzers
C. Major Coagulation Testing Technologies
And Their Potential Applications
VIII. COUNTRY MARKET ANALYSES: MARKET SIZE, REAGENT AND INSTRUMENT SALES FORECASTS, VOLUME
Projections for 40 Procedures, Supplier Sales and Market Shares
- Canada
- Mexico
- USA
Table of Contents (continued)
IX. Competitive Assessments
The report provides strategic assessments of over 20 leading coagulation market
players and start-up companies with innovative technologies and
products, including:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Diagnostica Stago
Grifols
Helena Laboratories
IL/Werfen
Roche
Sekisui Diagnostics
Siemens Healthineers
Sysmex
Thermo Fisher, and others
